Your Lungs Aren't Sterile — and That's a Good Thing
For most of medical history, doctors assumed healthy lungs were completely germ-free. Any microbe found in the lung was considered an invader.
That assumption turned out to be wrong — and the correction has opened up an entirely new area of research.
A New Way of Seeing Lung Health
The human body hosts trillions of microorganisms — bacteria, fungi, viruses, even a group called archaea. Most people know about the gut microbiome. But the lungs have their own microbial community too.
It's smaller and more transient than the gut microbiome — meaning the organisms in your lungs shift constantly as you breathe in and out. But that doesn't mean it's unimportant. Growing evidence shows the lung microbiome plays an active role in keeping the immune system balanced, helping tissues repair themselves, and preventing harmful pathogens from taking hold.
The Immune Protein Working the Front Lines
One of the most important players in lung immunity is immunoglobulin A — or IgA. It's a type of antibody (a protein the immune system makes to recognize and neutralize threats). In the lungs, a specific form called secretory IgA (sIgA) coats the airway lining.
Think of sIgA as a bouncer at the door of a club. It identifies unwanted visitors — viruses, bacteria, toxins — and blocks them from getting inside the cells of the airway. But it also plays a more nuanced role: it helps determine which microbes are allowed to stay and even shapes the composition of the microbial community itself.
When the Partnership Breaks Down
In healthy lungs, the microbiome and IgA work in a balanced partnership. The microbiome helps train and calibrate the immune system. IgA responds to the microbes present, helping to maintain a stable, protective community.
But in people with chronic lung diseases — including COPD (chronic obstructive pulmonary disease), asthma, and bronchiectasis (a condition where airways become permanently widened and prone to infection) — this balance is disrupted.
The microbial community becomes less diverse or shifts toward harmful species. IgA responses become dysregulated (out of balance). The result is a lung environment that is either chronically inflamed or poorly defended — sometimes both at once.
What This Review Examined
Researchers synthesized current scientific literature on the lung microbiome, its composition in health and disease, and its bidirectional (two-way) relationship with secretory IgA. They looked at what factors influence how IgA and the microbiome interact — including age, genetics, infections, antibiotics, and chronic disease — and what happens when those interactions go wrong.
The review confirmed that the lung microbiome and secretory IgA are in constant conversation. Specific microbes can trigger IgA responses, and those IgA responses in turn shape which microbes survive in the lung. It's a feedback loop, not a one-way street.
In disease states, this feedback loop breaks. In COPD patients, for example, the microbial community tends to become dominated by pro-inflammatory bacteria, while IgA responses become less specific and less effective. In people with recurrent lung infections, the protective coating of sIgA on airway surfaces is often diminished or dysfunctional.
This doesn't mean probiotic supplements or any available therapy will fix your lung microbiome today.
Where This Fits in the Bigger Picture
This field sits at the intersection of immunology (the study of immune systems) and microbiology (the study of microorganisms). For most of the 20th century, these were studied separately. The emerging picture — that the immune system and the microbial world it lives with are co-dependent — is reshaping how researchers think about chronic disease.
In the lung specifically, this matters because so many common conditions involve both immune dysregulation and microbial imbalance. Targeting the IgA-microbiome axis could offer a new route to treatment that current anti-inflammatory drugs simply don't address.
If you have a chronic lung condition, this research reinforces the importance of protecting your respiratory health holistically. Avoiding unnecessary antibiotics (which disrupt microbial balance), not smoking, and staying up to date on respiratory vaccines are all things that support the microbiome-IgA system — even before targeted therapies exist.
Talk to your pulmonologist (lung specialist) if you're experiencing recurrent lung infections or worsening inflammation that hasn't responded well to standard treatment.
Limitations Worth Knowing
This is a review article, not a clinical trial. The lung microbiome is genuinely harder to study than the gut microbiome — samples are difficult to collect consistently, and contamination during collection is a known problem. Much of what's known comes from research in specific disease populations, and findings may not apply uniformly to all patients or all lung conditions.
Researchers are now working to identify specific microbial signatures that predict disease progression or treatment response in lung conditions. There's particular interest in whether boosting or restoring IgA function — through mucosal vaccines or microbiome-targeted therapies — could stabilize the lungs of patients with recurrent infections or progressive disease. Clinical trials targeting this axis are beginning to take shape, though most remain years away from reaching patients.
